Accuray Incorporated (ARAY)
NASDAQ: ARAY · Real-Time Price · USD
1.490
+0.130 (9.56%)
May 8, 2025, 4:00 PM EDT - Market closed
Accuray Revenue
Accuray had revenue of $113.24M in the quarter ending March 31, 2025, with 11.98% growth. This brings the company's revenue in the last twelve months to $465.25M, up 8.06% year-over-year. In the fiscal year ending June 30, 2024, Accuray had annual revenue of $446.55M, down -0.24%.
Revenue (ttm)
$465.25M
Revenue Growth
+8.06%
P/S Ratio
0.32
Revenue / Employee
$471,379
Employees
987
Market Cap
153.49M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 446.55M | -1.05M | -0.24% |
Jun 30, 2023 | 447.61M | 17.70M | 4.12% |
Jun 30, 2022 | 429.91M | 33.62M | 8.48% |
Jun 30, 2021 | 396.29M | 13.36M | 3.49% |
Jun 30, 2020 | 382.93M | -35.86M | -8.56% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Abbott Laboratories | 42.34B |
ARAY News
- 1 day ago - Accuray Showcases New Long-Term Data¹ on Benefits of 5 Session Radiotherapy Treatment for Men with Prostate Cancer at ESTRO 2025 - PRNewsWire
- 3 days ago - Accuray Announces First SRS/SBRT Patient Treatments in Austria With the CyberKnife® System - PRNewsWire
- 6 days ago - Accuray: Tariffs Are The Latest Obstacle For A Company That Has Struggled To Deliver (Rating Downgrade) - Seeking Alpha
- 8 days ago - Accuray Incorporated (ARAY) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Accuray Reports Fiscal 2025 Third Quarter Financial Results - PRNewsWire
- 5 weeks ago - Accuray CyberKnife® Platform Featured in New Studies Showcasing its Benefits in Central Nervous System Tumors Presented at Radiosurgery Society Scientific Meeting - PRNewsWire
- 2 months ago - Accuray to Participate at 37th Annual Roth Conference - PRNewsWire
- 3 months ago - Accuray Incorporated (ARAY) Q2 2025 Earnings Call Transcript - Seeking Alpha